NLRP3 and colitis: In colitis models, the modulation of Th1/Th2 and Tregs/Th17 cell balance, alongside the inhibition of the NLRP3 inflammasome, remodeled the gut microbiota, providing new therapeutic strategies for patients with colitis (124).